CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- 4 Planned sale Sinha Vikas sold 2,707 shares at an average $1.56 ($4,220)
- 4 Planned sale Chief Executive Officer sold 1,325 shares at $1.98 ($2,619)
- 4 Planned sale Sinha Vikas sold 755 shares at $1.98 ($1,492)
- 4 Planned sale Chief Accounting Officer sold 222 shares at $1.98 ($439)
- 4 Planned sale Sinha Vikas sold 10,516 shares at $2.50 ($26,243)
- 4 Planned sale Chief Executive Officer sold 15,416 shares at an average $2.57 ($39,664)
- 4 Planned sale Chief Accounting Officer sold 1,653 shares at $2.50 ($4,125)
- 4 Planned sale Chief Executive Officer sold 8,342 shares at $3.56 ($29,710)
- 4 Planned sale Chief Accounting Officer sold 684 shares at an average $3.45 ($2,363)
- 4 Planned sale Sinha Vikas sold 2,635 shares at an average $3.44 ($9,077)
- 4 Planned sale Chief Executive Officer sold 5,275 shares at $3.05 ($16,063)
- 4 Planned sale Sinha Vikas sold 2,983 shares at $3.05 ($9,084)
- 4 Grant or award Chief Commercial Officer acquired 147,000 shares (grant or award)
- 4 Open-market buy 10% owner bought 2,930,870 shares at $3.75 ($10,990,763)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Accounting Officer sold 5,045 shares at $5.64 ($28,453)
- 4 Planned sale Chief Executive Officer sold 4,536 shares at $4.21 ($19,115)
- 4 Grant or award Director acquired 35,000 shares (grant or award)
- 4 Grant or award Director acquired 35,000 shares (grant or award)
- 4 Grant or award Director acquired 35,000 shares (grant or award)
Page 8 of 19 · 363 filings